Q1 2018 13F Holders as of 31 Mar 2018
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
20,525,249
-
Share change
-
+1,130,055
-
Total reported value
-
$525,648,455
-
Put/Call ratio
-
61%
-
Price per share
-
$25.61
-
Number of holders
-
54
-
Value change
-
+$33,400,079
-
Number of buys
-
27
-
Number of sells
-
31
Institutional Holders of AKCEA THERAPEUTICS INC - COM (AKCA) as of Q1 2018
As of 31 Mar 2018,
AKCEA THERAPEUTICS INC - COM (AKCA) was held by
54 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,525,249 shares.
The largest 10 holders included
FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, BB BIOTECH AG, BlackRock Inc., VANGUARD GROUP INC, STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, ALTRINSIC GLOBAL ADVISORS LLC, EVENTIDE ASSET MANAGEMENT, LLC, and NORTHERN TRUST CORP.
This page lists
54
institutional shareholders reporting positions in this security
for the Q1 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.